Metabolic Health
FDA Approves Two New Weight Loss Drugs in Record Two-Week Span
Foundayo and Zepbound receive rapid FDA approval for chronic weight management in adults with obesity or weight-related conditions.
Drug Approval
Apr 5, 2026 0
All Articles
4 articles
Metabolic Health
FDA Approves Two New Weight Loss Drugs Foundayo and Zepbound for Obesity
FDA approves Foundayo (orforglipron) and Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight conditions.
Drug Approval
Apr 4, 2026 0
Cancer Research
FDA Fast-Tracks Zongertinib for HER2-Mutated Lung Cancer in February 2026
New targeted therapy receives accelerated approval for specific non-small cell lung cancer subtype with HER2 mutations.
Drug Approval
Apr 3, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutated Lung Cancer Treatment
New targeted therapy offers hope for patients with specific genetic mutations in advanced non-small cell lung cancer.
Drug Approval
Apr 2, 2026 0